HealthBeacon PLC HealthBeacon - HBCN - Trading Update Year Ended 31.12.2022

Healthbeacon

17/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230217:nRSQ2186Qa&default-theme=true

RNS Number : 2186Q  HealthBeacon PLC  17 February 2023

Trading Update for the Year Ended 31 December 2022

HealthBeacon grows deployments, builds out sales and operations
infrastructure.

Dublin, 16 February 2023: HealthBeacon plc ("HealthBeacon" or "the Company"),
a leader in devices and software to manage critical and chronic medications,
today issues a trading update for the year ended 31 December 2022 in advance
of full year results to be announced on 31 March 2023.

HealthBeacon continued to make progress across all parts of its business
throughout 2022:

·   14,756 technology deployments (13,224 units and 1,532 patients on the
Patient Safety Platform) (2021: 10,187, units only).

·   The Company continued to build out sales infrastructure with additional
customers, drugs and geographies added across the specialty pharma and pharma
client base. It now has 28 contracted clients (2021: 23) including Evernorth,
NHS, Accord Healthcare and Clonmel Healthcare.

·   Included on Evernorth's Digital Health Formulary, which connects
employers, insurers, and patients with innovative, affordable, and
evidence-based care that meet their broader health care needs. Significant
technology deployments on track to commence H1 this year with a blockbuster
drug with multiple indications.

·    Specialty Pharmacy organizations in the US market distribute high
value medications that are complex in clinical logistics and patient
management, typically indicated for chronic illnesses such as arthritis.
HealthBeacon has approved projects with 3 of the top 5 Specialty Pharmacy
Organisations.

·   Novartis - Successful delivery from HealthBeacon across multiple
medications in the Irish market and sustainable management through Green Labs.

·   Developed Patient Safety Platform deployed to 1,532 patients launching
in the UK and Ireland markets. Australia and New Zealand to launch in 2023.
The Company now has 13 clients on this platform generating 2022 Revenue
€0.35m (2021: Nil) and ARR Revenue of €0.8m.

·   The supply chain disruption experienced in the first half of 2022 was
overcome through extensive liaison with key supply chain partners and the
onboarding of new strategic suppliers to overcome component availability
issues.  Early indications in 2023 are that the availability and cost
pressures experienced in the first half of 2022 continue to subside.

·   In partnership with clients, HealthBeacon continues to innovate and
extend the application of the technology platform enhancing patient outcomes.
 The development of the HB Wave for oral medication management is a response
to a significant need from clients and will integrate seamlessly with the
Company's existing technology platform. HealthBeacon also launched the HB
Smart Scale that syncs seamlessly with the Smart Sharps Bin technology device
and platform.  These innovations will support growth in 2024 and beyond.

 The Board reiterates its revenue guidance of €25m (ARR-Annual Recurring
 Revenue) revenue run rate by the end of Q1 2024 and adjusts the guidance on
 100,000 units from end of Q1 2024 to end of Q2 2024.  Unit deployment with
 Evernorth will commence in Q2 and ramp up significantly through the remainder
 of 2023. A second and subsequent speciality pharmacy organisations will launch
 early Q3 and into Q4 with unit deployment ramping up through Q4.  This,
 together with other deployments, will see the Company achieve an early to
 mid-teens euro revenue run rate (ARR) by the end of 2023. The medium term
 opportunity remains significant and the Company is very well positioned to
 grow meaningfully over the coming quarters and years.

 The Company will release its full year results for the year ended 31 December
 2022 on Friday 31 March 2023.

 

 

 

 Enquiries:                                       Investor.Relations@HealthBeacon.com
                                                  (mailto:Investor.Relations@HealthBeacon.com)
 HealthBeacon:

 Jim Joyce

 Lar Malone

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Paul Clifford                                    +353 (0) 87 327 2161

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates with its existing technology. The Company operates across Europe,
North America and the United Kingdom and employs more than 70 people and has
obtained more than 30 design and utility patents. The Company's mission is to
become the world's leading digital therapeutics platform for patients managing
medications in the home.

Ends

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISENKABNKBKBCBD